Favaretto et al. assessed the clinical significance of lower E-cadherin levels in an international cohort of 678 UTUC patients who were treated with RNU (60), observing that downregulation of E-cadherin in tumor cells correlated with adverse clinicopathological features. The gene discussed is CDH1; the disease is renal pelvis/ureter urothelial carcinoma.